MELBOURNE Australia, 12 September, 2016: AdAlta Limited (ASX: 1AD), the biotechnology company specialising in the discovery and development of protein-based therapeutics has entered an agreement with FujiFilm Diosynth Biotechnologies to manufacture AdAlta’s lead drug molecule for the treatment of idiopathic pulmonary fibrosis.
The agreement will see the process development, formulation and manufacture of AdAlta’s lead i-body molecule AD-114 by FujiFilm using its proprietary pAVEway™ advanced protein platform, an innovative technology for the production of proteins in bacteria, which has been proven in the expression of more than 90 biologics.
FujiFilm Diosynth Biotechnologies is one of the world’s leading global biologics and vaccines contract development and manufacturing organisations with development and manufacturing sites in Billingham (United Kingdom), North Carolina and Texas (United States) with over 1,000 employees.
Materials produced under the agreement at Fujifilm’s facility in Billingham in the United Kingdom will be used for animal and toxicology studies.
FujiFilm Diosynth Biotechnologies CEO Steve Bagshaw said, “We are looking forward to applying our versatile pAVEway™ expression system with such an innovative company as AdAlta with its unique i-body platform, and helping the company bring its novel biologic treatment, AD-114, to patients in need.”
AdAlta CEO Sam Cobb said, “The execution of this contract is an important step forward in the manufacture of our lead candidate. We have been impressed with the work already completed by the team at FujiFilm and expect to proceed rapidly with manufacturing of preclinical material for animal and clinical studies.”
Notes to Editors
AdAlta Limited is an Australian based drug development company headquartered in Melbourne. The Company is focused on using its proprietary technology platform to generate i-bodies, a new class of protein therapeutics, with applications as therapeutic drugs to treat disease.
The i-body is a human analogue of the antigen binding domain of the shark antibody, which combines the advantages of monoclonal antibodies (high target specificity and affinity) with the beneficial stability features of small molecules. In addition to stability, the i-body has a long binding loop that is a feature of shark antibodies not present in either human or next generation antibodies. This feature enables the i-body to recognise and bind to a diverse range of different therapeutically-relevant drug targets, including those that are difficult/intractable to access by current antibody therapies. These include clinically important targets such as G-protein coupled receptors (GPCRs) and ion channels.
AdAlta is developing its lead i-body candidate, AD-114, for the treatment of idiopathic pulmonary fibrosis (IPF) and other human fibrotic diseases, for which current therapies are sub-optimal and there is a high-unmet medical need.
The Company also plans to continue further drug discovery and development directed towards other drug targets and diseases with its i-body technology platform.
Further information can be found at: www.adalta.com.au
At the Company
Chief Executive Officer
Tel: +61 (0) 3 9479 5159
Tel: +61 (0) 408 677 734
Sue Charles/Daniel Gooch
Tel: +44 (0) 20 7866 7905